143 related articles for article (PubMed ID: 25212887)
21. Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.
Byrne M; Salmasinia D; Leather H; Cogle CR; Davis A; Hsu JW; Wiggins L; Chang MN; An Q; Wingard JR; Moreb JS
Clin Med Insights Oncol; 2014; 8():101-5. PubMed ID: 25232286
[TBL] [Abstract][Full Text] [Related]
22. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
23. Treatment options for relapsed and refractory multiple myeloma.
Nooka AK; Kastritis E; Dimopoulos MA; Lonial S
Blood; 2015 May; 125(20):3085-99. PubMed ID: 25838342
[TBL] [Abstract][Full Text] [Related]
24. Novel agents and new therapeutic approaches for treatment of multiple myeloma.
Ria R; Reale A; Vacca A
World J Methodol; 2014 Jun; 4(2):73-90. PubMed ID: 25332907
[TBL] [Abstract][Full Text] [Related]
25. Panobinostat for the treatment of multiple myeloma.
Rajkumar SV
Lancet Oncol; 2014 Oct; 15(11):1178-9. PubMed ID: 25242046
[No Abstract] [Full Text] [Related]
26. Allogeneic stem cell transplantation for multiple myeloma.
Bensinger W
Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK
Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
30. Treatment of patients with multiple myeloma over 65 yr: more tolerability or better response?
Tarkun P; Atalay F; Atesoglu EB; Mehtap O; Simsek M; Terzi E; Geduk A; Balli F; Batman A; Baydemir C; Hacihanefioglu A
Eur J Haematol; 2015 May; 94(5):424-30. PubMed ID: 25220635
[TBL] [Abstract][Full Text] [Related]
31. Elotuzumab, First-in-Class Monoclonal Antibody Immunotherapy, Improves Outcomes in Patients with Multiple Myeloma.
Starr P
Am Health Drug Benefits; 2015 Aug; 8(Spec Issue):17. PubMed ID: 26380608
[No Abstract] [Full Text] [Related]
32. Carfilzomib-induced nephrotoxcity.
Jhaveri KD; Wanchoo R
Kidney Int; 2015 Jul; 88(1):199-200. PubMed ID: 26126100
[No Abstract] [Full Text] [Related]
33. Evolving treatments in multiple myeloma patients with renal failure.
Gozzetti A; Papini G; Candi V; Bocchia M
Rev Recent Clin Trials; 2014; 9(4):276-9. PubMed ID: 25329484
[TBL] [Abstract][Full Text] [Related]
34. Curing myeloma at last: defining criteria and providing the evidence.
Barlogie B; Mitchell A; van Rhee F; Epstein J; Morgan GJ; Crowley J
Blood; 2014 Nov; 124(20):3043-51. PubMed ID: 25293776
[TBL] [Abstract][Full Text] [Related]
35. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G; Anderson KC
CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
[TBL] [Abstract][Full Text] [Related]
36. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
37. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
Roy A; Kish JK; Bloudek L; Siegel DS; Jagannath S; Globe D; Kuriakose ET; Migliaccio-Walle K
Am Health Drug Benefits; 2015 Jun; 8(4):204-15. PubMed ID: 26157542
[TBL] [Abstract][Full Text] [Related]
38. FDA approves new agent for multiple myeloma.
Fenichel MP
J Natl Cancer Inst; 2015 Jun; 107(6):djv165. PubMed ID: 26032612
[No Abstract] [Full Text] [Related]
39. Treatment-related symptom management in patients with multiple myeloma: a review.
Colson K
Support Care Cancer; 2015 May; 23(5):1431-45. PubMed ID: 25646616
[TBL] [Abstract][Full Text] [Related]
40. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
